Status:
COMPLETED
Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
PreDiabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The goal of this randomized clinical trial is to determine the impact of the risk haplotype on SLC16A11 on early therapeutic responses in treatments to prevent T2D in Mexican mestizos with prediabetes...
Detailed Description
Objectives: Dietary modification and/or metformin remain the most cost-effective treatment to prevent type 2 diabetes (T2D). Yet, there is an important variation in receiving the benefit among individ...
Eligibility Criteria
Inclusion
- Mexican mestizos
- At least one prediabetes criteria according to the American Diabetes Association: fasting glucose between 100-124 mg/dL, Glycosylated hemoglobin (HbA1c) between 5.7-6.4, and 2-hour blood sugar between 140 mg/dl-199 mg/dl after an oral load of 75g of glucose) (1);
- Age ranged between 18-65 years
- Overweight or obesity (BMI between 25.0 - 40 kg/m2).
Exclusion
- Chronic diseases
- Pregnancy
- Chronic use of medications that altered plasma glucose levels.
Key Trial Info
Start Date :
April 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
437 Patients enrolled
Trial Details
Trial ID
NCT05990205
Start Date
April 17 2018
End Date
March 1 2024
Last Update
May 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico, 14080